



Arvinas to Participate in Upcoming Investor Conferences

June 3, 2024

NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

- **Jefferies Global Healthcare Conference** on Thursday, June 6 in New York City.
 - John Houston, Ph.D., Chairperson, Chief Executive Officer and President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available [here](#) and on the Events + Presentations section of the Company's website.
- **Goldman Sachs 45th Annual Global Healthcare Conference** on Monday, June 10 in Miami.
 - John Houston, Ph.D., Chairperson, Chief Executive Officer and President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available [here](#) and on the Events + Presentations section of the Company's website.

About Arvinas

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC[®] Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC[®] targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and "undruggable" targets, the company has three investigational clinical-stage programs currently enrolling: vepdegestrant for the treatment of patients with locally advanced or metastatic ER+/HER2-breast cancer; ARV-102 for the treatment of patients with neurodegenerative disorders, and ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC[®] androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. For more information, visit www.arvinas.com.

Contacts

Investors:

Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:

Kathleen Murphy
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com